Rafael Marcos-Gragera1, Sandra Mallone2, Lambertus A Kiemeney3, Loreto Vilardell4, Núria Malats5, Yves Allory6, Milena Sant7. 1. Epidemiology Unit and Girona Cancer Registry (Oncology Coordination Plan), Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute, Girona, Spain. Electronic address: rmarcos@iconcologia.net. 2. National Centre for Epidemiology Surveillance and Health Promotion (CNESPS), National Institute of Health (Istituto Superiore di Sanità), Rome, Italy. 3. Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, The Netherlands. 4. Epidemiology Unit and Girona Cancer Registry (Oncology Coordination Plan), Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute, Girona, Spain. 5. Genetic and Molecular Epidemiology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. 6. APHP, Hôpitaux Universitaires Henri Mondor, Créteil, France. 7. Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Abstract
BACKGROUND: This work presents relative survival estimates regarding urinary tract tumours among adult patients (age⩾15years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000-2007, and on survival time trends from 1999-2001 to 2005-2007. METHODS: Data on 677,340 adult urinary tract tumour patients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries. The complete approach was used to estimate survival in 2000-2007; the period approach was used to estimate survival over time. RESULTS: The age-standardised 5-year relative survival for patients with kidney tumours diagnosed in Europe during 2000-2007 was 60%. The best prognosis was observed in Southern and Central Europe and prognosis improved in all regions along the time period. For invasive and non-invasive patients with bladder tumours combined the age-standardised 5-year relative survival in Europe was 68%. The best prognosis was observed in Southern and Northern Europe. However, in Scotland and The Netherlands the relative survival was significantly lower, although the survival estimates for these two countries were based on invasive tumours only. CONCLUSIONS: Differences in registration practices affect comparisons of survival values between European countries, especially in patients with urinary bladder cancers. The between-country variation in survival is influenced by the varying use of diagnostic investigation in urinary tract tumours. Further data on stage at diagnosis can help to elucidate the influence of diagnostic intensity or early diagnosis on the survival patterns.
BACKGROUND: This work presents relative survival estimates regarding urinary tract tumours among adult patients (age⩾15years) diagnosed in Europe. It reports on survival estimates of cases diagnosed in 2000-2007, and on survival time trends from 1999-2001 to 2005-2007. METHODS: Data on 677,340 adult urinary tract tumourpatients, (429,154 cases of invasive and non-invasive bladder and 248,186 cases of invasive kidney cancers) diagnosed between 2000 and 2007 were provided by 86 population-based cancer registries from 29 European countries. The complete approach was used to estimate survival in 2000-2007; the period approach was used to estimate survival over time. RESULTS: The age-standardised 5-year relative survival for patients with kidney tumours diagnosed in Europe during 2000-2007 was 60%. The best prognosis was observed in Southern and Central Europe and prognosis improved in all regions along the time period. For invasive and non-invasive patients with bladder tumours combined the age-standardised 5-year relative survival in Europe was 68%. The best prognosis was observed in Southern and Northern Europe. However, in Scotland and The Netherlands the relative survival was significantly lower, although the survival estimates for these two countries were based on invasive tumours only. CONCLUSIONS: Differences in registration practices affect comparisons of survival values between European countries, especially in patients with urinary bladder cancers. The between-country variation in survival is influenced by the varying use of diagnostic investigation in urinary tract tumours. Further data on stage at diagnosis can help to elucidate the influence of diagnostic intensity or early diagnosis on the survival patterns.
Authors: M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez Journal: Clin Transl Oncol Date: 2017-07-17 Impact factor: 3.405
Authors: Giovanni Barchetti; Giuseppe Simone; Isabella Ceravolo; Vincenzo Salvo; Riccardo Campa; Francesco Del Giudice; Ettore De Berardinis; Dorelsa Buccilli; Carlo Catalano; Michele Gallucci; James W F Catto; Valeria Panebianco Journal: Eur Radiol Date: 2019-03-18 Impact factor: 5.315
Authors: J Galceran; A Ameijide; M Carulla; A Mateos; J R Quirós; D Rojas; A Alemán; A Torrella; M Chico; M Vicente; J M Díaz; N Larrañaga; R Marcos-Gragera; M J Sánchez; J Perucha; P Franch; C Navarro; E Ardanaz; J Bigorra; P Rodrigo; R Peris Bonet Journal: Clin Transl Oncol Date: 2017-01-16 Impact factor: 3.405
Authors: Mohd Nasrullah Nik Ab Kadir; Suhaily Mohd Hairon; Najib Majdi Yaacob; Azizah Ab Manan; Nabihah Ali Journal: Int J Environ Res Public Health Date: 2021-05-14 Impact factor: 3.390